Legend Biotech jumped Monday after the company said its J&J-tied multiple myeloma drug, Cavykti, cut the risk of death.

Legend Biotech (LEGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell ...

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Legend Biotech (LEGN – Research Report) today and set a price target of ...

Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings ...

Legend Biotech's valuation is conservative, suggesting potential for significant appreciation and growth ahead. Click here to ...

On Friday, Legend Biotech Corp (LEGN) stock saw a modest uptick, ending the day at $49.27 which represents a slight increase of $2.42 or 5.17% from the prior close of $46.85. The stock opened at ...

After several years spent honing its robotic cell therapy manufacturing system, Multiply Labs has snared its first ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.94% of ...

Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets ...